Inge Dierynck

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

Anthony Mills, Mark Nelson, Dushyantha Jayaweera et al. · AIDS · 2009 · 266 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

James C. Sullivan, Sandra De Meyer, Doug J. Bartels et al. · Clinical Infectious Diseases · 2013 · 165 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier

Inge Dierynck, Mieke De Wit, Emmanuel Gustin et al. · Journal of Virology · 2007 · 158 citations

Life Sciences, Infectious Diseases, Molecular Biology +17

Potent Inhibition of Both Human Interferon-γ Production and Biologic Activity by the Clara Cell Protein CC16

Inge Dierynck, A. Bernard, Harry A. Roels et al. · American Journal of Respiratory Cell and Molecular Biology · 1995 · 147 citations

Life Sciences, Immunology, Pharmacology +17

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

Tara L. Kieffer, Sandra De Meyer, Doug J. Bartels et al. · PLoS ONE · 2012 · 87 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17